Omega-3 Fatty Acids, Lutein and Zeaxanthin: study protocols
12 study groups took Omega-3 Fatty Acids together with Lutein and Zeaxanthin. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Omega-3 Fatty Acids
12 study groups in 11 studies say how much Omega-3 Fatty Acids participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 50% of 12 study groups.
| Daily dose | Study groups |
|---|---|
| 50 mg or less | 1 |
| 50 mg to 100 mg | 2 |
| 100 mg to 250 mg | 1 |
| 250 mg to 500 mg | 1 |
| 500 mg to 1 g | 6 |
| 1 g to 2.5 g | 1 |
Dose per serving from research: Lutein
12 study groups in 11 studies say how much Lutein participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 5 mg to 10 mg, 100% of 12 study groups.
| Daily dose | Study groups |
|---|---|
| 5 mg to 10 mg | 12 |
Dose per serving from research: Zeaxanthin
12 study groups in 11 studies say how much Zeaxanthin participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 mg to 2.5 mg, 75% of 12 study groups.
| Daily dose | Study groups |
|---|---|
| 500 mcg or less | 1 |
| 500 mcg to 1 mg | 1 |
| 1 mg to 2.5 mg | 9 |
| 2.5 mg to 5 mg | 0 |
| 5 mg to 10 mg | 0 |
| 10 mg to 25 mg | 0 |
| over 25 mg | 1 |
Commonly used together
9 of 12 study groups took Omega-3 Fatty Acids, Lutein and Zeaxanthin with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Docosahexaenoic Acid | 7 |
| Vitamin E | 3 |
12 study groups
| Study | |||||
|---|---|---|---|---|---|
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 650 mg | 10 mg | 2 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · lutein/zeaxanthin and DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 1 g | 10 mg | 2 mg | 1789 days | — |
| No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18 2019 · Lutein and zeaxanthin plus omega-3 fatty acids · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye | 1 g | 10 mg | 2 mg | 5 years | — |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 100 mg | 10 mg | 2 mg | 12 weeks | 96 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 100 mg | 10 mg | 2 mg | 24 weeks | 40 |
| TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD 2007 · Sham MCS and nutritional supplement · Adults aged 50–90 with dry age-related macular degeneration in at least one eye | 300 mg | 8 mg | 400 mcg | 24 weeks | 37 |
| Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial 2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes | 650 mg | 10 mg | 2 mg | 5 years | — |
| A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on neural processing speed and efficiency 2014 · Multi · Healthy adults aged 18–32 years | 190 mg | 8 mg | 26 mg | 120 days | 25 |
| Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease 2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported | 650 mg | 10 mg | 2 mg | 1 year | 50 |
| Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial 2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified | 30 mg | 10 mg | 1 mg | 1 year | — |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 1.05 g | 10 mg | 2 mg | — | 10 |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 650 mg | 10 mg | 2 mg | 5 years | — |